Corporate:Pepe CarmonaChief Financial Officer(215) email@example.comJeannie Sorenson, M.D.Vice President, Investor Relations(314) firstname.lastname@example.org
ATHLONE, Ireland, Nov. 14, 2016 (GLOBE NEWSWIRE) -- Innocoll Holdings plc (Nasdaq:INNL), a global, specialty pharmaceutical and medical device company with late stage development programs targeting areas of significant unmet medical need, today announced that Anthony Zook, Chief Executive Officer of Innocoll Holdings plc, will participate in a fireside chat at the Stifel 2016 Healthcare Conference on Wednesday, November 16, 2016, at 8:45 a.m. ET at the Lotte New York Palace Hotel in New York, NY. About Innocoll Holdings plc Innocoll is a global, specialty pharmaceutical company with late stage development programs that is dedicated to engineering better medicines to help patients get better. Our proprietary, biocompatible, and biodegradable collagen products are precision-engineered for targeted use. Applied locally to surgery sites, they are designed to provide a range of benefits. The company's late stage product pipeline is focused on addressing a number of large unmet medical needs, including: XARACOLL for the treatment of postoperative pain and COLLAGUARD (INL-003), a barrier for the prevention of post-surgical adhesions. Our currently approved products include: COLLAGUARD® (ex-US), COLLATAMP® G, SEPTOCOLL® E, REGENEPRO®, COLLACARE®, COLLEXA®, and ZORPREVA®.